Stocks closed solidly higher on Thursday for the fourth straight session as investor optimism about the Trump administration continues to run high.

As 2024 was drawing to a close, OpenAI CEO Sam Altman faced two major problems. He wasn’t getting enough server capacity from Microsoft, his company’s biggest backer, to stay ahead of rivals ...

Today on Rising, Robby Soave delivers radar on why Mark Zuckerberg, Elon Musk, Jeff Bezos and others have flocked to President Trump’s side. Robby and Niall Stanage react to key parts of Trump’s ...

President Donald Trump on Thursday shrugged off an ugly back-and-forth between tech CEOs Elon Musk and Sam Altman that pitted one of Trump’s most visible lieutenants against a key participant in a ...

The S&P 500 gained 0.5% on Thursday, Jan. 23, reaching a record close as President Donald Trump pressed for lower oil prices ...

Moderna shares closed up Thursday gaining momentum following recent comments by Oracle Chairman Larry Ellison about the role of artificial intelligence in revolutionizing cancer treatment.

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 12,155 calls trading, 1.0x expected, and implied vol increasing almost 2 ...

Robby Soave and Niall Stanage weigh in on debate of using A.I. to develop mRNA vaccines to target cancer. #AI #mrnavaccines ...

Bryan Johnson highlights Larry Ellison's views on AI revolutionizing healthcare, particularly in cancer detection, treatment, ...

On Tuesday, OpenAI, SoftBank, Oracle, and MGX announced plans to form Stargate, a new company that will invest $500 billion ...

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...